M&A Deal Summary |
|
|---|---|
| Date | 2022-02-03 |
| Target | Lowenco |
| Sector | Manufacturing |
| Buyer(s) |
Impilo
SHS Capital |
| Deal Type | Buyout (LBO, MBO, MBI) |
| Advisor(s) | Brown Gibbons Lang (BGL) (Financial) |
SEARCH BY
Impilo is a private investment firm focused exclusively on on investments in Nordic companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo prefers majority investments, but will consider select minority situations. Target companies are generally valued between SEK 200 million and SEK 1.5 billion. Impilo has offices in Stockholm and Copenhagen.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 10 |
| Sector: Manufacturing M&A | 1 of 1 |
| Type: Buyout (LBO, MBO, MBI) M&A Deals | 8 of 8 |
| Country: Denmark M&A | 4 of 4 |
| Year: 2022 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-01-03 |
tandlægen
Lyngby, Denmark tandlægen is a dental care chain, that comprises 52 clinics across all regions in Denmark, employs over 800 professionals and serves more than a quarter of a million patients per year. tandlægen was formed in 2016 and is based in Lyngby, Denmark. |
Buy | - |
SHS Capital is a private equity firm focused on the healthcare sector. Specific areas of interest include life science, medical technology, diagnostics, applied technologies, digital health, and industrial biotechnology. The Firm will consider opportunities at all company stages and looks to commit up to €50 million in businesses valued up to €150 million. Target geographies include Germany, Austria, Switzerland, Scandinavia, and Benelux. SHS Capital was established in 1993 and is headquartered in Tubingen, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 30 of 35 |
| Sector: Manufacturing M&A | 1 of 1 |
| Type: Buyout (LBO, MBO, MBI) M&A Deals | 7 of 9 |
| Country: Denmark M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-07-01 |
evitria
Zurich, Switzerland evitria is a biotechnology company specialized in protein expression. evitria AG offers custom monoclonal antibodies and comparable molecules as well as gene expression services. evitria has been conducting more than 40,000 transfections. Customers of evitria are typically renowned pharmaceutical and biotechnology companies as well as research institutions. The customers have a constant demand for specific proteins tailored to the respective research purposes they use evitria as a highly specialized outsourcing partner. evitria was founded in 2010 and is based in Zurich, Switzerland. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-02-15 |
c-LEcta
Leipzig, Germany c-LEcta is a developer of enzymes and microbial strains for industrial biotech applications in food, feed, pharma, and chemistry; a self-developed technology platform for the development of new enzymes. c-LEcta was founded in 2004 and is based in Leipzig, Germany. |
Sell | - |
